Figure 6

The effects of ASA VI on p-AKT expression in OVX rBMSCs.
(A) Western blotting was used to analyze p-AKT expression after a 48-hour ASA VI 10−5 M treatment, with or without LY294002. (B) The Western blotting results were analyzed using Quantity One Bio-Rad software. The data are represented as the mean ± SD. **P < 0.01 vs the controls; ###P < 0.001 vs ASA VI 10−5 M.